SG11201408398UA - Compositions and methods for regulating car t cells - Google Patents
Compositions and methods for regulating car t cellsInfo
- Publication number
- SG11201408398UA SG11201408398UA SG11201408398UA SG11201408398UA SG11201408398UA SG 11201408398U A SG11201408398U A SG 11201408398UA SG 11201408398U A SG11201408398U A SG 11201408398UA SG 11201408398U A SG11201408398U A SG 11201408398UA SG 11201408398U A SG11201408398U A SG 11201408398UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- cells
- methods
- regulating car
- regulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261671518P | 2012-07-13 | 2012-07-13 | |
PCT/US2013/050272 WO2014011987A1 (en) | 2012-07-13 | 2013-07-12 | Compositions and methods for regulating car t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408398UA true SG11201408398UA (en) | 2015-02-27 |
Family
ID=49916567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408398UA SG11201408398UA (en) | 2012-07-13 | 2013-07-12 | Compositions and methods for regulating car t cells |
Country Status (14)
Country | Link |
---|---|
US (3) | US20150140019A1 (de) |
EP (1) | EP2872218A4 (de) |
JP (1) | JP2015525765A (de) |
KR (1) | KR20150030724A (de) |
CN (1) | CN104507537A (de) |
AU (1) | AU2013289970A1 (de) |
BR (1) | BR112015000310A2 (de) |
CA (1) | CA2878856A1 (de) |
EA (1) | EA201590207A1 (de) |
IL (1) | IL236679A0 (de) |
IN (1) | IN2014DN10889A (de) |
MX (1) | MX2015000428A (de) |
SG (1) | SG11201408398UA (de) |
WO (1) | WO2014011987A1 (de) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
RU2019137208A (ru) | 2013-02-20 | 2020-02-19 | Новартис Аг | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII |
EP3623380A1 (de) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting von zytotoxischen zellen mit chimären rezeptoren zur adoptiven immuntherapie |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
RU2714902C2 (ru) | 2013-12-19 | 2020-02-20 | Новартис Аг | Химерные рецепторы антигена против мезотелина человека и их применение |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
KR20240042250A (ko) | 2014-04-07 | 2024-04-01 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
RU2741120C2 (ru) | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
JP6815992B2 (ja) | 2014-10-08 | 2021-01-20 | ノバルティス アーゲー | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 |
EP3215521A4 (de) | 2014-11-06 | 2018-07-18 | University of Maryland, Baltimore | Cd8 und t-zellrezeptorvarianten und verfahren zur verwendung davon bei der modulation von immunzellantworten |
WO2016097231A2 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
EP3234130B1 (de) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Verfahren zum profiling vom t-zell-rezeptor-repertoire |
EP3234193B1 (de) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molekulare biomarker für krebsimmuntherapie |
IL303247A (en) | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
EP3250606B1 (de) | 2015-01-26 | 2020-11-25 | Cellectis | Anti-cll1-spezifische einkettige chimäere antigenrezeptoren(sccars) zur krebsimmuntherapie |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
US11896614B2 (en) | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
CN115058395A (zh) * | 2015-06-25 | 2022-09-16 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
WO2017015427A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
EP3339320A4 (de) * | 2015-08-17 | 2019-01-23 | Seoul National University R&DB Foundation | Chimärer antikörperrezeptor mit daran angebundenem anti-cotinin-antikörper und verwendung davon |
EP3340995A4 (de) | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | Verfahren und zusammensetzungen für zellen zur expression eines chimären intrazellulären signalmoleküls |
EP3340998B1 (de) | 2015-08-28 | 2023-01-11 | The Trustees of the University of Pennsylvania | Verfahren und zusammensetzungen für zellen zur expression eines chimären intrazellulären signalmoleküls |
JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
US20190255107A1 (en) | 2015-10-09 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
CN117866991A (zh) | 2016-10-07 | 2024-04-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
SI3580561T1 (sl) | 2017-02-12 | 2024-04-30 | Biontech Us Inc. | Metode, osnovane na hla, in njihove sestave ter uporabe |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
MX2019012398A (es) | 2017-04-18 | 2020-09-25 | Broad Inst Inc | Composiciones para detectar secreciones y metodos de uso. |
EP3638218A4 (de) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | Zusammensetzungen und verfahren zum targeting von komplementierender komponente 3 zur hemmung des tumorwachstums |
JP2020530277A (ja) | 2017-06-30 | 2020-10-22 | セレクティスCellectis | 反復投与のための細胞免疫療法 |
CN111511388A (zh) | 2017-09-21 | 2020-08-07 | 博德研究所 | 用于靶向核酸编辑的系统、方法和组合物 |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | Car t细胞的使用方法 |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
US20210324357A1 (en) | 2018-08-20 | 2021-10-21 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
US20210355522A1 (en) | 2018-08-20 | 2021-11-18 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease activity and uses thereof |
WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
EP3942023A1 (de) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
CN114729384A (zh) | 2019-09-12 | 2022-07-08 | 博德研究所 | 工程化腺相关病毒衣壳 |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
AR120563A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quimérico cd19 y cd22 y sus usos |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
CN117677632A (zh) * | 2021-07-21 | 2024-03-08 | 韩国生命工学研究院 | 新型嵌合抗原受体和表达该嵌合抗原受体的免疫细胞 |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4792447A (en) * | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
DE60142684D1 (de) * | 2000-03-29 | 2010-09-09 | Univ Ohio State Res Found | Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen |
US7514537B2 (en) * | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
AU2004308494B2 (en) * | 2003-12-23 | 2010-03-18 | Genentech, Inc. | Novel anti-IL 13 antibodies and uses thereof |
US20090304721A1 (en) * | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
JP5727786B2 (ja) * | 2007-10-19 | 2015-06-03 | シアトル ジェネティクス,インコーポレーテッド | Cd19結合性物質およびその使用 |
DE102010039018B4 (de) * | 2010-08-06 | 2013-02-28 | Technische Universität Dresden | Anti-La Antikörper und ihre Anwendung zum Immunotargeting |
BR122021026169B1 (pt) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
ES2791716T3 (es) * | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
-
2013
- 2013-07-12 EP EP13816421.5A patent/EP2872218A4/de not_active Withdrawn
- 2013-07-12 WO PCT/US2013/050272 patent/WO2014011987A1/en active Application Filing
- 2013-07-12 SG SG11201408398UA patent/SG11201408398UA/en unknown
- 2013-07-12 CN CN201380037380.XA patent/CN104507537A/zh active Pending
- 2013-07-12 IN IN10889DEN2014 patent/IN2014DN10889A/en unknown
- 2013-07-12 US US14/408,851 patent/US20150140019A1/en not_active Abandoned
- 2013-07-12 CA CA2878856A patent/CA2878856A1/en not_active Abandoned
- 2013-07-12 KR KR20157000921A patent/KR20150030724A/ko not_active Application Discontinuation
- 2013-07-12 BR BR112015000310A patent/BR112015000310A2/pt not_active Application Discontinuation
- 2013-07-12 MX MX2015000428A patent/MX2015000428A/es unknown
- 2013-07-12 AU AU2013289970A patent/AU2013289970A1/en not_active Abandoned
- 2013-07-12 EA EA201590207A patent/EA201590207A1/ru unknown
- 2013-07-12 JP JP2015521840A patent/JP2015525765A/ja active Pending
-
2015
- 2015-01-12 IL IL236679A patent/IL236679A0/en unknown
-
2018
- 2018-12-11 US US16/216,460 patent/US20190367610A1/en not_active Abandoned
-
2022
- 2022-05-03 US US17/735,624 patent/US20230034117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2015525765A (ja) | 2015-09-07 |
EP2872218A4 (de) | 2016-07-06 |
US20150140019A1 (en) | 2015-05-21 |
BR112015000310A2 (pt) | 2017-06-27 |
EP2872218A1 (de) | 2015-05-20 |
WO2014011987A1 (en) | 2014-01-16 |
MX2015000428A (es) | 2015-03-12 |
EA201590207A1 (ru) | 2015-05-29 |
CA2878856A1 (en) | 2014-01-16 |
AU2013289970A1 (en) | 2015-01-22 |
US20190367610A1 (en) | 2019-12-05 |
KR20150030724A (ko) | 2015-03-20 |
IL236679A0 (en) | 2015-02-26 |
CN104507537A (zh) | 2015-04-08 |
IN2014DN10889A (de) | 2015-09-11 |
US20230034117A1 (en) | 2023-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL236679A0 (en) | Preparations and methods for regulating car t cells | |
IL272539B (en) | Preparations and methods for immunotherapy | |
HK1251246A1 (zh) | 用於使組合物脫硫的方法和組合物 | |
ZA201502884B (en) | Compositions and methods for modulating cell signaling | |
SG10201705024PA (en) | Methods and compositions for separating or enriching cells | |
EP2892523A4 (de) | Verfahren und zusammensetzungen zur regeneration von haarzellen und/oder unstützung von zellen | |
EP2922861A4 (de) | Biomarkerzusammensetzungen und verfahren | |
EP2823306A4 (de) | Biomarkerzusammensetzungen und verfahren | |
EP2850184A4 (de) | Zusammensetzungen und verfahren zur modulation von genexpression | |
EP2850183A4 (de) | Zusammensetzungen und verfahren zur modulation von genexpression | |
EP2862226A4 (de) | Elektrochemische suspensionszusammensetzungen und verfahren zur herstellung davon | |
HUE061931T2 (hu) | Módszerek és készítmények természetes ölõsejtek számára | |
EP2850189A4 (de) | Zusammensetzungen und verfahren zur modulation von genexpression | |
SG11201500799YA (en) | Hla g-modified cells and methods | |
HK1205942A1 (en) | Compositions, methods, and kits for regulating energy metabolism | |
IL237916A0 (en) | Preparations and methods for preparing glycoproteins | |
ZA201407412B (en) | Method and compositions for preventing stem cell disruption and aggregation | |
HK1212733A1 (zh) | 富含維生素發酵物的組合物和方法 | |
IL239484A0 (en) | Materials for omitting enterprise-tumor cells | |
EP2852662A4 (de) | Herpesviruszusammensetzungen und zugehörige verfahren | |
GB201220058D0 (en) | Cell differentiation | |
IL239529B (en) | Preparations and methods for creating improved and different cells and organisms | |
HK1210436A1 (en) | Novel cell compositions and methods | |
IL239426A0 (en) | Methods and compositions of biomarkers | |
EP2931293A4 (de) | Zusammensetzungen und verfahren zur regulierung der erythropoiese |